Background: Hymenoptera venom allergy (HVA) is an underestimated condition representing an important cause of morbidity and mortality worldwide. Preventing future allergic reactions in patients who have already developed a systemic reaction is based on the correct management of the acute phase of the reaction followed by a correct diagnosis and, where indicated, prescription of adrenaline autoinjectors and VIT. A possible strategy to optimize care processes and to improve outcomes is the implementation of a Diagnostic and Therapeutic Care Pathways, also known as Integrated Care Pathways or Clinical Pathways (CPWs). The aim of the care pathway is to enhance the quality of care by improving risk-adjusted patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. To our knowledge, currently in Italy as well as in Europe, there is no CPWs codified for the management of HVA patients. This paper describes the development of the clinical content of a care pathway for the management of HVA.
Background
Hymenoptera venom allergy (HVA) is an underestimated condition representing an important cause of morbidity and mortality worldwide. It can occur with varying degrees of severity (from local to anaphylactic reactions) and can sometimes be fatal. According to the data from the European Anaphylaxis Registry, HVA is the first Bilò et al. Clin Transl Allergy (2020) 10:8 cause of severe reactions in adults and the second in children (48.2% and 20.2% respectively) [1] . In different countries, HVA is responsible for about 20% of the total cases of fatal anaphylaxis [2] . Overall, the incidence of mortality in the various European countries is between 0.03/million/year in Italy and 0.48 in France. However, mortality data are generally underestimated, as deaths are likely to be attributed by mistake to other causes, in particular to cardiac disorders. Moreover, up to 8% of adult patients with HVA may simultaneously suffer from a systemic mastocytosis (SM). SM is a clonal mast cell (MC) disease that can lead to potentially fatal anaphylactic reactions caused by excessive MC mediator release. Anaphylaxis is the most severe clinical manifestation of SM and is characterized by hypotension and syncope in the absence of urticarial and angioedema [3] .
Hymenoptera venom allergy diagnosis is based on clinical history and results of in vivo and in vitro tests (mainly, specific IgE detection) [4] . Skin tests are the gold standard for diagnosis and should be carried out at least 2 weeks after the last sting, to exclude a false negative response during the refractory period. The presence of serum specific IgE to Hymenoptera venoms can be detected immediately after sting, even if the best period for their determination is 1-4 weeks after the sting. Diagnosis could be complicated by sensitization to multiple venoms (Apis mellifera/vespids or Vespula spp./Polistes dominula) in patients who have not identified the stinging Hymenoptera. The availability on the market of some major allergens expressed in recombinant form allows evaluating the specific IgE to individual molecular markers (CRD, Component-Resolved-Diagnosis). CRD may discriminate between primary sensitization and crossreactivity in patients with double and multiple positivity of diagnostic tests with whole extracts [5] .
As for therapy, adrenaline is the treatment of choice for acute anaphylaxis; it slows the progression of symptoms and can prevent the development of fatal or biphasic reactions [6] . All patients with a history of an anaphylactic reaction should be provided with an adrenaline autoinjector [7] . Venom immunotherapy (VIT) is the most effective treatment for subjects who developed a systemic allergic reaction (SR) after Hymenoptera sting, since currently it is the only treatment able to effectively prevent SR in case of a re-sting even after its discontinuation [8] .
Preventing future allergic reactions in patients who have already developed a SR is based on the correct management of the acute phase of the reaction followed by a correct diagnosis and, where indicated, prescription of an adrenaline autoinjector and VIT.
A possible strategy to optimize care processes and to improve outcomes is the implementation of Diagnostic and Therapeutic Care Pathways, also known as Integrated Care Pathways or Clinical Pathways (CPWs). CPWs are complex interventions for mutual decisionmaking, organization and standardization of predictable care for a well-defined group of patients during a welldefined period [9] .
The aim of the care pathway is to enhance the quality of care by improving risk-adjusted patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources [9] . Clinical pathways are primarily considered to be tools for designing care processes, implementing clinical governance, streamlining delivered care, improving the quality of clinical care and ensuring that clinical care is based on the latest research.
Standardization of the clinical care process through integration of evidence-based knowledge has proven to be an effective strategy for reducing unwanted variations in treatment, minimizing the probability of medical errors and improve the quality of the healthcare [10, 11] . The reduction of variability is in fact the key to quality.
Evidence-based clinical pathways can be effective tools for organizing evidence into multidisciplinary care plans for local work processes and can be a model for making evidence more actionable for providers at the point of care [12] . To our knowledge, currently in Italy as well as in Europe, there is no CPWs codified for the management of HVA patients.
This paper describes the development of the clinical content of a care pathway for the management of HVA.
Methods
The methodology applied is based on the eight-step method to build the clinical content of an evidence-based care pathway as suggested by Lodewijckx et al. [10] . The steps applied for the development of the model pathway are shown below.
Selection of an expert panel
A national expert panel was involved in each step of the development of the model pathway, in order to guarantee the clinical validity and practicability of the path.
The expert panel consisted of seven doctors with clinical and scientific expertise in HVA, two doctors with clinical and scientific expertise in emergency medicine and two pharmacists.
Moreover, the expert panel was supported by a technical-methodological coordination group made of one medical doctor, with scientific expertise in development and implementation of care pathways, one medical allergist from the expert panel and two post-graduate medical doctors (one post-graduate medical doctor in Allergy and Clinical Immunology and another one in Hygiene and Preventive Medicine and Public Health).
A first face-to-face meeting of the panel members was conducted in July 2018 to choose the protocol for search, evaluation and synthesis of best evidence for the realization of the CPW.
Literature search and selection of recommendations
To identify the reference guidelines (LGs) an extensive literature review was conducted from July 2018 up to September 2018, with the aim of identifying the good practices to be included in the document.
The following resources were explored: (i) websites of European Academy of Allergy and Clinical Immunology (https ://www.eaaci .org/); (ii) websites of The American Academy of Allergy, Asthma and Immunology (https :// www.aaaai .org/); (iii) National Institute for Health and Clinical Excellence (NICE) (www.nice.org.uk); (iv) electronic database (Medline).
For Medline, the following terms were used: "guidelines" combined with "anaphylaxis", "adrenaline" "Hymenoptera venom allergy", "venom immunotherapy", and "Systemic mastocytosis" combined with "Hymenoptera venom allergy", "Allergy", "Anaphylaxis". All synonyms for these terms were included in the search.
Participants were given the opportunity to provide any additional recommendations from other good quality supplementary documents (Position Paper and Review) or, alternatively, to produce specific recommendations indicated as Good Practice Point (GPP), in the absence of evidence of effectiveness in the selected LGs.
The selected literature was thoroughly screened for identification of all possible recommendations by the members of the technical-methodological coordination group. The recommendations were extracted and listed both in English and Italian languages, and the corresponding literature sources were recorded.
Delphi consensus method
The Delphi method was used in order to select relevant statements [13] .
Two rounds were used to reach consensus. The first Delphi survey was conducted through email between October 2018-November 2018. In the first round, the panelists rated the relevance of each recommendations on a scale of 1 to 9, with 1 being certainly irrelevant and 9 being certainly relevant. They have also had the chance to record comments to explain their scores.
Completed score-sheets with any comments were then returned by email to the technical-methodological coordination group. The scores and comments were recorded onto a central database file. Feedback on the round one responses was provided to all panelists through central tendencies (median, mode) of each statement.
All panel members attended the second round faceto-face meeting, which occurred in December 2018, to discuss the results of the first round. The same analysis procedure was applied to the second round rating during the meeting. Consensus was defined as agreement by at least 75% of the panel members. All the statements that were rated 8 or 9 by at least 75% of the panelists in round two have been included in the final clinical pathway.
Selection of key interventions
One of the active ingredients in care pathways is the integration of a set of evidence-based key interventions (KI) that may assist clinicians in selecting the best treatment options and in delivering safe and effective care.
Therefore, the selected recommendations were translated into key interventions. Each key intervention has been included a detailed description (rationale), which addresses the reason why the key intervention is performed (illustrating the expected impact on patient outcomes) and a description of the intervention (core activity), as a set of good quality tests, which define the exact content of the key intervention to be guaranteed to the patient.
The core activities allow contextualization of specific operating activities in greater details and meet a series of criteria: (i) core activities almost always require to be carried out by a specific member of the clinical care team (doctor, nurse, pharmacist etc.); (ii) core activities need to be carried out at a specific point in the treatment pathway or at a specific stage.
Translation into a set of clinical indicators
To study the quality of care and the impact of care pathways appropriately, a valid and feasible set of process and outcome indicators needs to be defined. Therefore, besides the set of key interventions, it was necessary to develop a set of process and outcome indicators to verify compliance to key interventions and to follow up the impact on outcomes.
Clinical indicators are measures of clinical care which may, when assessed over time, provide a method of assessing the quality and safety of care. They are measures of the process or outcomes of patient care and they are used by health systems and services to identify areas of concern which might require further review or development. They are potentially important tool designed to help clinicians and healthcare organizations to assess the quality of care being provided against agreed evidence bases recommendations [14] .
The key interventions that had obtained an average score higher than 8.8 were translated into a set of clinical indicators, which are relevant to study quality of care and impact of care pathways in HVA patients. The reason for choosing this assessment threshold is that identifying one or more indicators for each of the selected recommendations would have led to the production of a large number of indicators and standards difficult to measure. The group was given the opportunity to integrate the list with further adequately motivated performance indicators.
According to the commonly used Donabedian Model, quality of healthcare can be measured by three types of indicators: structure, process and outcome indicators [14] . In the HVA CPW only process indicators have been identified. The process indicator measures the appropriateness and completeness of information obtained through clinical history, physical examination, diagnostic tests; justification of diagnosis and therapy; technical competence in the performance of diagnostic and therapeutic procedures, evidence of preventive management in health and illness; coordination and continuity of care and therapy [15] .
Flow-diagram development
Finally, a process flow diagram was developed. CPWs can be viewed as algorithms as much as they offer a flow chart format of the decisions to be made and the care to be provided for a given patient or patient group for a given condition in a step-wise sequence; these detail the recommended algorithm of actions and level of care. The hierarchical algorithm is a snapshot of the process at its highest level; it focuses the user's attention on the main decision nodes. It provides a mental model for the multidisciplinary team and helps to manage complexity [15] .
Results
Seventeen publications, among which six were international guidelines, were identified from literature search, which were screened for identification of all possible statements/recommendations [3, [6] [7] [8] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
There was no need to review any evidence with a GPP judgment from the panel of experts.
Three hundred and seventeen different recommendations were extracted from the selected literature. The expert panel was involved in their evaluation, expressing a judgment of relevance through the Delphi method. One hundred twelve recommendations had score (median, mode) higher than eight, one hundred ten recommendations had reached the agreement of at least 75% of the panel and were including in the CPW. Out of the remaining 205 recommendations, 202 had score between 4 and 7.9 and three had score lower than 4. The participants received a report, which illustrated the results of the first evaluation for each recommendation. A subsequent consensus meeting was held with the entire expert panel in order to discuss in the areas of disagreement and other two recommendations (out of 112) with score (median, mode) higher than eight that had not reached the agreement at 75% and recommendations with 4-7.9 score to make a final selection. The discussion then focused on the areas of disagreement that emerged. Consensus was reached for 16 of 204 recommendations.
As a result, 126 recommendations were appraised to be valid and feasible. They were categorized into five groups: 10 statements on emergency treatment of patients with HVA (ET), 27 statements on diagnosis of HVA (D), 26 statements on pharmacological therapy (PT), 47 statements on immunotherapy (VIT) and finally 16 on mastocytosis and HVA (M).
The final recommendations (126) were then translated into 123 key interventions (similar recommendations have been combined into a single key intervention). An example of a key intervention (rational and core activity) is provided in Fig. 1 . All key interventions are listed in Table 1 .
The key interventions were presented by means of a process flow diagram (Fig. 2) . All the flow chart forms were numbered in order to link them to the recommendations and related key interventions.
Six process indicators were produced by the recommendations that had obtained an average score higher than 8.8 (Table 2) . Figure 3 summarizes the development of the clinical pathway and its results.
Finally, the document was submitted to a panel of other 17 specialists responsible for Allergy Departments in Italy, who did not produce any additional remarks, in particular about KI and indicators. The core activities will then be included within Operative pathways, which are the real representation of routes at the local level, based on resources and available skills. The final document was then shared with the Italian Federation of patient associations (FederAsma e Allergie onlus). Specific questions from patient's point of view asked by the Italian Federation found their answer in different parts of the document (KI and flow-chart).
Discussion
Hymenoptera venom allergy is an important cause of morbidity worldwide and may occur with varying degrees of severity and can sometimes be fatal.
The management of the patients who have developed a SR after a Hymenoptera sting provides for a correct management in the emergency treatment, followed by a correct diagnosis that forms the basis for the treatment, represented by the prescription of an adrenaline autoinjector, and VIT, where necessary.
CPWs are used to improve quality of care, standardize care and maximize the outcomes for specific groups of patients [11] . A CPW with the goal to increase the level of medical awareness on HVA and outline clear care paths for these patients is lacking. Therefore, this document aims to identify a shared, multidisciplinary path, based on the most recent national and international scientific evidence (quality guidelines were used for the most part) and supported by the consensus of different specialists with extensive experience in emergency treatment (2) and clinical expertise and scientific knowledge of HVA (7) . The multidisciplinary expert group was fundamental for the development of the CPW, making it possible to deal comprehensively with the management of the HVA patients.
The main objective is to standardize the behavior of professionals with regard to taking care, diagnosis, treatment and follow-up of allergic patients with systemic reactions due to Hymenoptera stings, so as to ensure the maximum degree of appropriateness of the interventions and health services and minimizing the degree of variability in clinical decisions.
Professional uncertainty and the scarce use of medical evidence seem to be the key elements in many problems dealing with health care variations, due to their possible links with medical errors. Reducing variations by standardizing clinical processes is an effective tool to minimize the probability of medical errors [29] .
Given that HVA is the most frequent cause of severe allergic reactions, and still an epidemiologically underestimated condition, this codified approach also allows a better assessment of the impact of the disease and its epidemiological weight.
Moreover, we developed a set of indicators, which are potentially important tools able to help clinicians and healthcare organizations to assess the quality of care being provided by agreed evidence-based recommendations. Therefore, the selected indicators are relevant for research on quality of management of HVA patients. -Rational Specific immunotherapy for hymenoptera venom is the therapy of choice for subjects who developed a systemic reaction after hymenoptera sting or developed a systemic skin reaction at high risk of exposition and/or impairment of quality of life or finally in patient with clonal mast cell disease, since it can induce a tolerance to venom and it able to protect patients from systemic reaction after subsequent stings -Core Activity Indicate VIT to a) adults and children with a systemic reaction involving other apparatus besides the skin. b) systemic skin reaction at high risk of exposition and/or impairment of quality of life. c) patients with clonal mast cell disorder and a history of a systemic reaction, even though sensitization can be weak or sometimes transitory
Key intervention
Key intervention [16] Base the diagnosis of anaphylaxis on the history and physical examination, using scenarios described by the National Institutes of Allergy and Infectious Disease (NIAID) Panel but recognizing that there is a broad spectrum of anaphylaxis presentations that require clinical judgment. Do not rely on signs of shock for the diagnosis of anaphylaxis Diagnose anaphylaxis using scenarios described by the NIAID panel, and do not rely only on shock signs I12, I13 ES3 [7] For diagnosis of doubtful reactions, collect blood (ideally within 1-2 h but no later than 4 h from the onset of symptoms) for serum tryptase testing (3 ml clotted sample, serum separated and froze) Dose serum tryptase, within 4 h, in case of a doubtful reaction I3 ES4 [7] Record the daily medication and any additional self-medication taken on the day of the sting, in particular ACE inhibitor or beta-blocker
Record drug therapy assumed on the day of the sting, paying close attention to cardiological and/or hypotensive therapies I2 ES5 [28] Glucagon sometimes needed in patients taking a beta-adrenergic blocker who have hypotension and bradycardia and who do not optimally respond to adrenaline. Glucagon can be administered in adult patients intravenously at a dose of 1 mg as an initial IV bolus, repeatable every 5 min, increasing the dosage to 3-5 mg if necessary. The administration for continuous infusion in syringe pump should be carried out at the dose of 1-5 mg/h
Administer glucagone in patients under beta-blocking therapy with hypotension and low heart rate when they do not react optimally to adrenaline administration, taking into consideration it is an "off-label" therapy I2
ES6
[28] The patient, after receiving the appropriate therapies and obtained the resolution of clinical picture, should be kept under observation and monitored for at least 6-8 h up to 24 h depending on severity and characteristics of the reaction at onset, comorbidity and risk factors
Observe and monitor the patient after clinical resolution for at least 6-8 h and up to 24 h depending on the patient's clinical conditions I4, I5, I6, I7 ES7 [7] After emergency treatment for suspected ISA, prescribe the patient (or, as appropriate, their parent and/or caregivers) an AAI that is appropriate for age and body mass. Patients must receive a referral to a specialist allergy service
Prescribe an adrenaline auto-injector after emergency treatment of the insect sting anaphylaxis I10, I19 [28] Allergy to bumble bees, due to its low aggressiveness, concerns a limited number of subjects, in particular professionally exposed individuals [8] , and it should therefore be investigated on the basis of a specific anamnestic suspicion, provided that a suitable extract is commercially available for diagnosis In case of a suspected clinical history, perform diagnostic investigations for Bumble bee also with the aim of prescribing a possible VIT I12, I13 PT5 [28] In obese or overweight patients, the reduced length of the needle does not always ensure the intramuscular administration, therefore the patient should be advised to press well the autoinjector on fatty thigh, to compress it and allow the penetration of the needle into the muscle Instruct obese patients to press well the autoinjector on fatty thigh to compress it and allow the penetration of the needle into the muscle I19 PT6 [28] If a correct dosage is administered, it can be used, without absolute contraindications, in pediatric and geriatric populations and in cardiopathic patients, except for some cardiac pathologies such as for example long QT syndrome (in this case, the administration should be performed with extreme caution, in case of real need and in the presence of the cardiologist)
Administer adrenaline in pediatric and geriatric population and in cardiopathic patients in case of anaphylaxis. In patients suffering from some cardiac pathologies, such as long QT syndrome, administer adrenaline in the presence of the cardiologist Link to flow-chart PT23 [7] Glucocorticoids in the treatment of anaphylaxis potentially relieve protracted anaphylaxis symptoms and are thought to prevent biphasic anaphylaxis, although these effects have never been proven Administer corticosteroids to relieve protracted anaphylactic symptoms (however not in adrenaline replacement) and probably to prevent biphasic anaphylaxis, although this effect has never been proven with controlled randomized trials I2 PT24 [7] Patients may receive a set of tablets containing an adequate dose of a rapidly effective non-sedating oral antihistamine (e.g. levocetirizine 10 mg, cetirizine 20 mg, or double dose for children according to the age) and corticosteroids (e.g. prednisone: for adults 50-100 mg and 1-2 mg/kg body weight in children VIT12 [28] VIT is indicated in the following circumstances: (a) Children and adults with a systemic reaction involving other apparatus besides the skin. (b) Systemic skin reactions at high risk of exposition and/or impairment of quality of life in adults. (c) Patients with clonal mast cell disorder and a history of a systemic reaction, even though sensitization can be weak or sometimes transitory VIT is indicated in: (i) adults and children with a systemic reaction involving other apparatus besides the skin; (ii) systemic skin reaction at high risk of exposure and/or impairment of quality of life; (iii) patients with clonal mast cell disorders and a history of a systemic reaction, even though sensitization can be sometimes transitory I20 VIT13 [28] In children with only cutaneous systemic reactions, VIT is not routinely performed. However, there may be particular situations of increased risk of re-sting (e.g. children of beekeepers), possibly associated with parents' and children's concern or with distance from the emergency room, or unavailability of school staff administering antiallergic drugs. These conditions warrant VIT also in cases of urticarial alone
Consider to perform VIT in children with only cutaneous systemic reactions if there are particular situations (e.g. increase risk of re-sting, concern, or distance from the Emergency Department, etc.) I20 VIT14 [17] In a change from previous recommendations, advise both children and adults who have experienced only cutaneous systemic reactions without other systemic manifestations after an insect sting that VIT is generally not required but may be considered when there are special circumstances. This should be a shared decision with consideration of high-risk factors (frequent exposure, cardiovascular or respiratory conditions, or selected medications) and the effects on quality of life Advise both children (and caregivers) and adults who have experienced only cutaneous systemic reactions after an insect sting that VIT is generally not required. VIT can be considered when there are special circumstances (cardiovascular or respiratory conditions, effects on quality of life) I20 VIT15 [28] In patients allergic to Hymenoptera venom, in whom a subsequent allergic reaction may be more severe or even fatal, VIT has an elective indication even if there has been a myocardial infarction or a severe ventricular arrhythmia Suggest VIT in cardiopathic venom allergic patients when a systemic reaction occurred I20, I21
VIT16 [28] VIT should be taken into consideration in older adults, even if they have experienced a non-severe systemic reaction, provided that they have risk factors such as: concomitant vascular diseases, treatment with ACE inhibitors and/ or beta-blockers, severe COPD pictures, reduced quality of life due to the previous anaphylactic event Link to flow-chart
[27] The European Competence Network on Mastocytosis recommends using the REMA score as a clinically useful tool to predict for the presence of clonal MCs prior to a BM study; the REMA score is based only on demographic data (gender), the symptoms and signs observed during the acute episodes, and serum baseline tryptase levels. A REMA score of at least 2 predicts with a high sensitivity and specificity for ISMs-(or c-MCAS), whereas a REMA score of less than 2 usually indicates non-clonal disease. The REMA score is a particularly helpful tool since it is based on clinical data and can be used on a routine clinical basis, it is associated with rather low costs, and it avoids unnecessary BM studies Use REMA score to predict a clonal mast cell disease before submitting the patients to bone marrow biopsy 10:8 Italian Federation of patient associations, which evaluated and shared the CPW.
Furthermore, we did not verify the indicators in specific clinical audits, which allows to obtain further information on the feasibility of data collection, on verification of adherence to the CPW and on any changes to effectively implement the path; however, this phase was not included in the project.
The next step of project is to translate and check the feasibility of the CPW at local Italian levels. This phase is particularly important as designing the care pathway content is a time-consuming process that requires resources and skills.
Conclusion
Developing the clinical care pathway may facilitate adequate integration of evidence-based knowledge into daily practice. For the first time in the field of HVA, by using the Delphi survey with 11 experts 123 key interventions were found to be appropriate for the development and standardization of the clinical content of the HVA care pathway. Next to the model pathway, six indicators were identified for monitoring and following up of Hymenoptera venom allergy patients.
Compliance to care pathways can be difficult, but has to be strived for, to deliver the best possible care for patients. LGs: Guidelines; SM: Systemic mastocytosis; SR: Systemic allergic reaction; MC: Mast cell.
